| Old Articles: <Older 42531-42540 Newer> |
|---|
 |
The Motley Fool
July 27, 2010
Brian Orelli |
Better Buy: Cell Therapeutics or Sequenom? Which one deserves your dollars more?   |
The Motley Fool
July 27, 2010
Rich Smith |
This Just In: Upgrades and Downgrades Barclays jumpstarts a rally at electric car battery-maker A123 Systems. |
The Motley Fool
July 27, 2010
Brian Orelli |
Branded? Generic? They're Both Doing Great! Teva Pharmaceuticals registers strong growth on both fronts. |
The Motley Fool
July 27, 2010
Anders Bylund |
Buy, Sell, or Hold STEC? Solid-state drives are the future, but does STEC have a place in it? |
The Motley Fool
July 27, 2010
Brian Orelli |
Brilinta? I Think Not. AstraZeneca's new blood thinner is far from brilliant. |
The Motley Fool
July 27, 2010
Sean Sun |
Risk Report Card: Amazon.com What's really interesting about Amazon is that it turns the traditional notions about technology-based companies on their head. |
The Motley Fool
July 27, 2010
Jordan DiPietro |
Some Banks Are Too Big to Fail? European finance ministers got together and decided to stress-test 91 banks to calm the credit markets and reduce fears of a broad collapse of EU financial institutions. |
The Motley Fool
July 27, 2010
Eric Jhonsa |
Will Qualcomm Stop Destroying Shareholder Value? Qualcomm's FLO TV mobile television business, which the company now appears ready to sell, has to rank among its most financially destructive boondoggles. |
The Motley Fool
July 27, 2010 |
Why We're Buying Fiserv Advisor Joe Magyer reveals why he thinks today's recommendation, Fiserv, is a great way to get into the banking world without all the risk. |
The Motley Fool
July 27, 2010
Selena Maranjian |
New Taxes Can't Stop These Dividends Even if the IRS raises rates, dividends remain potent portfolio powerhouses. |
| <Older 42531-42540 Newer> Return to current articles. |
